Molecular Portrait of Integrin Beta-6 (IB6): Characterization of IB6 Expression and Co-Mutation Patterns From the U.S. Real-world Data Study
AMP 2025
M. Fidler, L. Clinton, L. Hsu, J. Smith, S. Whitman, B. Li, P. Cronin, R. Gennarelli, E. Davis, J. Berndt, A. Brackey, D. Jenkins, D. Bloch, S. Bell, L. Walls, J. Borgia
Introduction
IB6, encoded by ITGB6, is highly expressed in several solid
tumors, including non-small-cell lung cancer (NSCLC), and is a promising
therapeutic target. The investigational IB6-directed antibody-drug
conjugate sigvotatug vedotin has shown encouraging activity in NSCLC
(Peters, ASCO 2024). Here are preliminary results from the IB6
Expression and Clinical Outcomes in NSCLC study, which was conducted
to characterize real-world IB6 expression and its clinical relevance, and
investigate potential association with established or exploratory
biomarkers in patients with metastatic NSCLC (mNSCLC). Methods: This
retrospective, real-world, observational study used the Tempus deidentified patient record database to examine data for US patients with
mNSCLC who had tumor sequencing data available after May 2019.
Patient demographics and clinical characteristics were obtained via
electronic health record integration and clinical record abstraction. Tissue
samples from primary or metastatic lesions underwent IB6
immunohistochemistry (IHC) and were manually scored by a pathologist
to characterize IB6 as high or low using a pre-specified method. The study
objectives included characterization of real-world IB6 expression by IHC
and exploration of the correlation between IB6 expression by IHC and
RNA level and association with other relevant NSCLC biomarkers,
including PD-L1, EGFR, ALK, KRAS, TACSTD2 (alias TROP2), and
cMET. Results: In the preliminary cohort of 129 patients, median age was
66 years; 52.7% were female, 47.3% were White, and 35.7% were Black
or African American. Of the tissue samples, 37.2% were from primary
tumors, and 68.2% had non-squamous histology. Prevalence of high IB6
expression in the 117 evaluable mNSCLC tumor samples was 70.9%. IB6
expression varied by histology, with high IB6 expression in 76.9% of nonsquamous and 42.1% of squamous samples. Median ITGB6 RNA
expression was significantly higher in the IB6-high versus -low cohort (6.3
log2[TPM+1] versus 3.7 log2[TPM+1]; P <0.001). Due to limited sample
size, the association of IB6 with PD-L1, TACSTD2, and cMET was
evaluated. Prevalence of PD-L1 expression (defined as tumor proportion
score ≥1%) was similar in the IB6-high and -low subgroups (65.1% versus
55.9%). Median RNA expression of TACSTD2 and cMET did not
significantly differ by IB6 expression status. Conclusions: In this sample
of diverse US patients with mNSCLC, high IB6 expression was common,
particularly in non-squamous histology, underscoring the potential of IB6
as a novel therapeutic target. Initial results support a correlation between
IB6 expression by IHC and RNA sequencing. No notable trend was
observed between IB6 expression status and PD-L1, TACSTD2, or cMET
expression. Further investigation of IB6-directed therapies is warranted.
Related publications